Jianfeng Group Lin2016 -026 (Announcement on Foreign Investment of Subsidists)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2016-026
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 本公司控股子公司浙江尖峰药业有限公司与德国葛芙制药有限公司、珠海横琴德运嘉国际贸易有限公司签订了《中外合资经营企业合同》,拟在中国浙江省金华市共同出资设立一家中外合资经营企业,致力于建成一个婴幼儿、儿童用药的制药企业。
l 尖峰药业本次拟出资人民币1100万元,占合营公司注册资本的55%。
l 合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
一、对外投资概述
(一)2016年7月12日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)与德国葛芙制药有限公司(以下简称:葛芙制药)、珠海横琴德运嘉国际贸易有限公司(以下简称:德运嘉)签订了《中外合资经营企业合同》,合营各方根据平等互利的原则和长期真诚合作的愿望,努力吸取各自专长和采用适宜的先进技术以及科学的管理方法成立合营公司,并致力于建成一个以婴幼儿、儿童用药制剂研发、生产和销售为主的现代化制药企业。
合营公司中文名称是:浙江金得尔儿婴药品有限公司(以下简称“合营公司”)(以工商行政管理部门核定的名称为准)。合营公司的注册资本为人民币2000万元,其中:尖峰药业以现金人民币1100万元出资,葛芙制药以专有技术的知识产权评估作价人民币500万元出资,德运嘉以现金人民币400万元出资。合营公司拟注册在中国浙江省金华市金西开发区。
(二)本次对外投资,尖峰药业的出资金额为人民币1100万元,根据本公司《章程》有关规定,在董事长对外投资审批权限范围之内,无需提交公司董事会、股东大会审议。
(三)该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、协议主题的基本情况
(一)德国葛芙制药有限公司
1、企业名称:德国葛芙制药有限公司(GOHOFF ARZNEIMITTEL GmbH)
2、企业性质:有限责任公司
3、注册地:德国柏林
4、注册日期:2016年3月24日
5、主要办公地点:德国柏林茵塞尔路17号
6、法定代表人:Katharina Bodmeier
7、注册资本:25000欧元
8、主营业务:药品、化学品、化妆品和保健品的开发、销售和贸易
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(欧元) |
出资比例 |
|
1 |
Prof.Dr.Roland Bodmeier |
12500 |
50% |
|
2 |
FangHuang |
11250 |
45% |
|
3 |
Katharina Bodmeier |
1250 |
5% |
(二)珠海横琴德运嘉国际贸易有限公司
1、企业名称:珠海横琴德运嘉国际贸易有限公司
2、企业性质:有限责任公司(自然人独资)
3、注册地:珠海市横琴新区
4、注册日期:2015年06月17日
5、主要办公地点:珠海市横琴新区宝华路6号105室-3754
6、法定代表人:李华智
7、注册资本:500万元人民币,截止公告日实收资本为240万元。
8、主营业务:从事货物与技术的进出口业务;贸易咨询、技术咨询、技术服务;化妆品及卫生用品进出口批发和零售;非许可类医疗器械经营;医疗用品和器材进出口批发和零售;草药和天然产品的进出口批发和零售;保健食品、乳制品进出口批发和零售;动物用健康食品、保健品和药品的进出口批发和零售;药品进出口批发和零售;预包装食品的批发和销售。
9、主要股东:李华智先生占公司注册资本100%。
10、主要财务指标:截止2015年12月31日,德运嘉的资产总额为27.35万元、资产净额5.93万元、营业收入48.54万元、净利润-4.07万元等;
三、合营公司的基本情况
1、企业名称:浙江金得尔儿婴药品有限公司(以工商行政管理部门核定的名称为准)
2、经营范围:保健品和药品进出口,研究、开发、生产和销售婴幼儿用药及其他生物及化学医药产品。
3、注册资本:2000万元人民币
4、出资方式:尖峰药业以现金出资人民币1100万元,占注册资本的55%;葛芙制药以“地西泮栓”、“对乙酰氨基酚栓”两项专有技术评估作价人民币500万元出资,占注册资本的25%;德运嘉以现金出资人民币400万元出资,占注册资本的20%。
5、董事会安排:合营公司董事会由5名董事组成,尖峰药业委派3人,葛芙制药委派1人,德运嘉委派1人。董事长由尖峰药业委派担任,副董事长由葛芙制药委派。董事长、副董事长和董事的任职期限应为四年。
6、管理层安排:合营公司设总经理1名和财务经理1名。总经理由葛芙制药委派,财务经理由尖峰药业委派,任期为四年。
7、无形资产出资情况:葛芙制药以其拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术作价500万元人民币进行出资。金华金辰资产评估有限公司对上述两项专有技术进行评估并出具了《评估报告》,评估价值为555.00万元(大写人民币伍佰伍拾伍万元)。葛芙制药所拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术不存在抵押、质押或者其他重大争议、诉讼或仲裁事项、查封或者冻结等司法措施。
地西泮栓是用于抗焦虑、睡眠障碍,增加肌肉张力的治疗药物;对乙酰氨基酚是用于感冒或感冒引起的发热,也用于缓解轻至中度疼痛。“地西泮栓”、“对乙酰氨基酚栓”都已经在德国上市。中国国家食品药品监督管理总局的网站显示已经有54个“对乙酰氨基酚栓”的批准文号;尚未有“地西泮栓”的批准文号, 但“地西泮”片剂、注射剂已经有较多的批准文号。合资公司成立后将以上述两项专有技术为基础进行相应产品的研发、经营。
四、合同的主要内容
2016年7月12日,尖峰药业(甲方)、葛芙制药(乙方)和德运嘉(丙方)签订了《中外合资经营企业合同》,主要条款有:
1、甲方、乙方和丙方三方将根据《中华人民共和国中外合资经营企业法》、《中华人民共和国中外合资经营企业法实施条例》等其他与本合同相关的法律、法规和规定,按照平等互利的原则,通过友好协商,一致同意在中国浙江省金华市共同设立中外合资经营企业。
2、合营公司注册资本为人民币2000万元。甲方出资额占注册资本的55%,其中以现金出资人民币1100万元。乙方出资额占注册资本的25%,其中以知识产权出资,以评估作价出资人民币500万元。丙方出资额占注册资本的20%,其中以现金出资人民币400万元。
3、以现金出资时,甲、丙双方应于2017年6月30日前缴付认缴的出资;以知识产权出资时,乙方应在公司成立之日起180工作日内,办理知识产权变更登记,将出资用知识产权所有权和使用权转移至合营公司。
4、合营公司租用甲方拥有的位于金华金西开发区尖峰药业制药基地内厂房。甲方同意该场地可用以建成合营公司的药品研发、生产基地。场地租金须不高于市场价,租赁协议另行签订。租赁期限应为中国法律允许的最长期限20年。
5、董事会是合营公司最高权力机构,合营公司的营业执照颁发之日为其董事会成立之日。合营公司的重大事项应由董事会全体一致决定。对于下列事项应由董事会全体董事一致通过方可做出决定:(1)合营企业章程的修改;(2)合营企业的中止、提前终止、解散、清算或延长合营公司期限;(3)合营企业注册资本的增加和减少;(4)合营企业的合并和分立;(5)合营各方向合营公司外的其他方转让股权。
除上述条款外的其它事项应由多数票通过决议决定,但是至少乙方或丙方委派的一名董事投了赞成票。
6、合营公司设总经理1 名和财务经理1 名。总经理应由乙方委派,财务经理应由甲方委派。他们的任期为四年,同样可根据董事会的决定连任。合营公司的其他高层管理人员,由总经理提议,董事会批准后聘请。
7、合营公司的合营期限为30年,从合营公司营业执照签发之日开始。
8、若合资公司决定解散,需进行清算。在制定和执行清算方案的过程中,清算委员会应尽可能将合营公司的产品、产品开发权益、知识产权、专有技术等分配给乙方和/或丙方。
9、除因不可抗力外,若本合同一方在实质性方面不完整、不恰当履行或终止履行本合同,在收到合营其他方通知后六十天内仍不纠正其违约行为时,该方便构成违约,违约方应承担责任,负责赔偿履约方或合营公司由此遭受的损失,赔偿上限不超过认缴的出资额或以非货币财产出资时的非货币财产。
10、本合同的效力,解释,执行,修改,终止及争议的解决,应适用中国法律。已公布的中国法律未涉及事宜,采用国际惯例。
11、在履行本合同及附件过程中发生的一切争议,各方首先应友好协商解决,如争议各方不能协商解决,则经各方书面同意,可将争议提交中国国际经济贸易仲裁委员会按其仲裁程序进行仲裁。仲裁语言采用中文,翻译成英文。仲裁裁决是终局的,并对各方均有约束力。
12、本合同自合营各方签字盖章,并经有权的审批机构批准后生效。
五、对公司的影响
随着我国人口政策的调整,“全面二胎”政策的实施,预计婴幼儿用药市场将迎来快速增长的机遇,本次尖峰药业通过组建合营公司,引进德国技术开发婴幼儿用药,符合公司的发展战略规划,是公司做大做强医药业务的具体实施。
六、可能存在的风险
本次签署的是《中外合资经营企业合同》,合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一六年七月十二日
More information
Peak health marketing and a new "play"
Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)
2020
07-30
2020
07-30
2020
07-31
2020
07-31
On January 23, the group company held a special working meeting to summarize the safety and environmental protection work in 2016 and make arrangements for the work in the new year. General manager Yu Jianhong pointed out at the meeting that hidden dangers are accidents, accidents should be assessed, and safety and environmental protection work should continue to be carried out with a "zero tolerance" attitude. At the meeting, Chen Tianci, assistant to the general manager of the group company and manager of the audit performance management department, summarized the safety and environmental protection work in 2016 from the aspects of the completion of the safety and environmental protection responsibility system objectives, self-examination and self-correction of illegal operations, and the establishment of safety and environmental protection accident-free factories, analyzed the problems existing in the work, and put forward the safety and environmental protection work plan for 2017 in a targeted manner. Jiang Xiaomeng, chairman of the group company, stressed at the meeting that the work of safety and environmental protection is endless and must be carried out unremittingly. All enterprises should focus on safety and environmental protection management in a planned and focused manner according to the characteristics of their respective industries and industries, seasonal changes, and national policy adjustments. It is more important to establish awareness than inspection. It is necessary to strengthen safety and environmental protection education and improve the safety and environmental protection awareness and related work skills of all employees. Conduct in-depth pre-inspection and strict post-assessment to achieve full management and comprehensive prevention, and realize the overall improvement of enterprise safety and environmental protection. At the meeting, Jiang Xiaomeng, on behalf of the group company, signed the 2017 safety and environmental protection work responsibility letter with various professional companies and directly affiliated enterprises. In his concluding speech, Yu Jianhong, general manager of the group company, pointed out that safety runs through the development of the enterprise, and safety and environmental protection cannot be separated from production and operation. The two promote each other and complement each other, and managers at all levels must have a deep level of this.
2020
07-31
"Spike" Cement Becomes Yunnan Famous Brand Product
News from our newspaper At the beginning of the new year, good news came from Yunnan Jianfeng Cement Company. The "Jianfeng" brand cement successfully passed the examination and approval and won the title of "Yunnan Famous Brand Product. Since it was put into production in 2013, the "Jianfeng" brand cement produced by Yunnan Jianfeng has won good sales performance and reputation in the southwest Yunnan market, and its popularity and brand influence have been continuously improved. Therefore, Yunnan Jianfeng started to declare "famous brand products" in 2016. After preliminary data preparation, preliminary examination by Pu'er Municipal Bureau of Quality and Technical Supervision, expert review by Yunnan Provincial Bureau of Quality and Technical Supervision and on-site verification, Yunnan Provincial Bureau of Quality and Technical Supervision finally passed the examination and approval of "Yunnan Famous Brand Products" organized by Yunnan Provincial Strategic Leading Group for Implementing Brand and Strong Quality Province in 2017. The acquisition of this honorary title will further enhance the market competitiveness of Jianfeng Cement in southwestern Yunnan, and also increase the popularity of Yunnan Jianfeng, laying a more solid foundation for further market development in the future. (Li Chun)
2020
07-31